Hypercortisolism and Epicardial Adipose Tissue

Impact Hypercortisolism on Adipose Epicardial and on Myocardial Function

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02335996

Acronym

Hyper-Cor

Enrollment

Registered

2015-01-12

Start date

2014-12-08

Completion date

2023-05-25

Last updated

2023-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercortisolism

Brief summary

Identifying hypercortisolism patients at risk for cardio-vascular events despite biological cure, and determine which patients should be particularly followed. Hypercortisolic patients represent an ideal in vivo model to determine the interactions between glucocorticoids and ectopic fat development.

Interventions

BIOLOGICALBlood samples for measuring adiponectin, leptin and omentin plasma

DEVICEMRI at 3 Tesla

Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Major, male or female * Introducing an active or healed hypercortisolism caused by Cushing's disease * signed informed consent.

Exclusion criteria

* Elderly patients under 18 years * Pregnant or lactating women * Previous history of myocardial infarction * Antecedent congenital cardiomyopathy * Adrenocorticotropic hormone-independent Hyperadrenocorticism * Hyperadrenocorticism by ectopic Adrenocorticotropic hormone secretion * Treatment with corticosteroids or insulin * Specific contraindication to the achievement of Nuclear Magnetic Resonance (metal heart valves, pacemakers, metallic foreign body, claustrophobia) * Persons deprived of liberty * Persons not affiliated to a social security scheme * People unable to give their consent in writing (in person or with the assistance of a third party).

Design outcomes

Primary

Measure	Time frame
measuring the volume of epicardial adipose tissue, as measured by MRI to 3 Tesla.	36 months
Assess insulin resistance by the blood sugar and insulin levels	36 months
Assess cardiovascular risk by a blood complete lipid profile	36 months

Secondary

Measure	Time frame
Assess cardiovascular risk by the blood leptin, adiponectin and omentin plasma level	36 months
Assess insulin resistance by the blood leptin, adiponectin and omentin plasma level	36 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026